Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joseph M. Sheridan is active.

Publication


Featured researches published by Joseph M. Sheridan.


Science | 2008

An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity

David J. Haydon; Neil R. Stokes; Rebecca Ure; Greta Galbraith; James M. Bennett; David R. Brown; Patrick J. Baker; Vladimir V. Barynin; David W. Rice; Sveta Sedelnikova; Jonathan R. Heal; Joseph M. Sheridan; Sachin T. Aiwale; Pramod K. Chauhan; Anil K. Srivastava; Amit Taneja; Ian Collins; Jeff Errington; Lloyd George Czaplewski

FtsZ is an essential bacterial guanosine triphosphatase and homolog of mammalian β-tubulin that polymerizes and assembles into a ring to initiate cell division. We have created a class of small synthetic antibacterials, exemplified by PC190723, which inhibits FtsZ and prevents cell division. PC190723 has potent and selective in vitro bactericidal activity against staphylococci, including methicillin- and multi-drug–resistant Staphylococcus aureus. The putative inhibitor-binding site of PC190723 was mapped to a region of FtsZ that is analogous to the Taxol-binding site of tubulin. PC190723 was efficacious in an in vivo model of infection, curing mice infected with a lethal dose of S. aureus. The data validate FtsZ as a target for antibacterial intervention and identify PC190723 as suitable for optimization into a new anti-staphylococcal therapy.


Archive | 2011

Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies

Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton; Ian Pike


Archive | 2011

CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS

Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton; Ian Pike


Organic and Biomolecular Chemistry | 2011

Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD

Yushma Bhurruth-Alcor; Therese H. Røst; Michael R. Jorgensen; Christos Kontogiorgis; Jon Skorve; Robert G. Cooper; Joseph M. Sheridan; William D.O. Hamilton; Jonathan R. Heal; Rolf K. Berge; Andrew D. Miller


Archive | 2012

Compositions and methods for the biosynthesis of vanillin or vanillin beta-d-glucoside

Joergen Hansen; Esben Halkjaer Hansen; Polur Honey; Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton


Archive | 2011

CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES

Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton; Ian Pike


Archive | 2008

1, 2, 4-triazole derivatives as serotonergic modulators

Jonathan R. Heal; Joseph M. Sheridan; William D.O. Hamilton; Simon James Grimshaw; Sorin Vasile Filip


Archive | 2013

Anthocyanins with Specific Properties

Jorgen Hansen; Patricia Hoyle; Michael Naesby; Joseph M. Sheridan; Jonathan R. Heal


Archive | 2017

CASEIN KINASE 1δ (CK1δ) INHIBITORS AND THEIR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES

Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton; Ian Pike


Archive | 2016

CASEIN KINASE 1 DELTA (CK 1 DELTA) INHIBITORS

Joseph M. Sheridan; Jonathan R. Heal; William D.O. Hamilton; Ian Pike

Collaboration


Dive into the Joseph M. Sheridan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge